Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields

Bioelectromagnetics

Volumn 31, Issue 3, 2010, Pages 237-245

  Girgert, Rainer ^a   Hanf, Volker ^b   Emons, Gunter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KLINIKUM FÜRTH   (Germany)

Author keywords

Breast cancer; Electromagnetic fields; Gene expression; Melatonin

Indexed keywords

BACTERIOPHAGES; CANCER CELLS; CELL CULTURE; DISEASES; ELECTROMAGNETIC FIELDS; HORMONES; SIGNAL TRANSDUCTION;

ANTI-ESTROGENIC; BREAST CANCER; BREAST CANCER CELLS; CELL LINES; ESTROGEN RECEPTOR; EXPOSED TO; GENES EXPRESSION; MCF-7 CELLS; MELATONIN; MELATONIN RECEPTORS;

GENE EXPRESSION;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CREB1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ESTRADIOL; MELATONIN; MELATONIN 1 RECEPTOR; MYC PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; BREAST TUMOR; ELECTROMAGNETIC FIELD; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PERIODICITY; PHYSIOLOGY; PROMOTER REGION; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ELECTROMAGNETIC FIELDS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MELATONIN; PERIODICITY; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, MELATONIN, MT1; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 77952022691     PISSN: 01978462     EISSN: 1521186X     Source Type: Journal    
DOI: 10.1002/bem.20554.     Document Type: Article

References (26)

1. Blackman CF, Benane SG, House DE. 2001. The influence of 1.2 microT, 60Hz magnetic fields on melatonin-and tamoxifen-induced inhibition of MCF-7 cell growth. Bioelectromagnetics 22:122-128.
2. Brydon L, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R. 1999. Dual signaling of human Mel1a melatonin receptors via G (i2), G (i3), and G (q/11) proteins. Mol Endocrinol 13:2025-2038.
3. Cohen M, Lippman M, Chabner B. 1978. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 2:814-816.
4. Cos S, Blask DE, Lemus-Wilson A, Hill AB. 1991. Effects of melatonin on the cell cycle kinetics and " estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 10:36-42.
5. Davis S, Mirick DK, Stevens RG. 2001. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557-1562.
6. Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V. 2003. Tracking the elusive antiestrogenic effect of melatonin: A new methodological approach. Neuro Endocrinol Lett 24:440-444.
7. Girgert R, Grundker C, Emons G, Hanf V. 2008. Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells. Bioelectromagnetics 29:169-176.
8. Girgert R, Hanf V, Emons G, Gründker C. 2009. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 47:23-31.
9. Hill SM, Blask DE. 1988. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48:6121-6126.
10. Ishido M, Nitta H, Kabuto M. 2001. Magnetic fields (MF) of 50 Hz at 1.2microT as well as 100microT cause uncoupling of inhibitory pathways of adenylyl cyclase mediated by melatonin 1a receptor in MF-sensitive MCF-7 cells. Carcinogenesis 22:1043-1048.
11. L'Hermite-Baleriaux M, de Launoit Y. 1992. Is melatonin really an in vitro inhibitor of human breast cancer cell proliferation? In Vitro Cell Dev Biol 28A: 583-584.
12. Liburdy RP, Sloma TR, Sokolic R, Yaswen P. 1993. ELF magnetic fields, breast cancer, and melatonin:60 Hz fields block melatonin's oncostatic action on ER+ breast cancer cell proliferation. J Pineal Res 14:89-97.
13. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. 1999. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65:415-420.
14. Molis TM, Spriggs LL, Jupiter Y, Hill SM. 1995. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 18:93-103.
15. Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P. 2000. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 7:347-351.
16. Panzer A, Lottering ML, Bianchi P, Glencross DK, Stark JH, Seegers JC. 1998. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett 122:17-23.
17. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. 1993. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4:57-65.
18. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. 2006. Night work and risk of breast cancer. Epidemiology 17:108-111.
19. Shah PN, Mhatre MC, Kothari LS. 1984. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 44:3403-3407.
20. Sharkey J, Olcese J. 2007. Transcriptional inhibition of oxytocin receptor expression in human myometrial cells by melatonin involves protein kinase C signaling. J Clin Endocrinol Metab 92:4015-4019.
21. Stanley ER, Palmer RE, Sohn U. 1977. Development of methods for the quantitative in vitro analysis of androgen-dependent and autonomous Shionogi carcinoma 115 cells. Cell 10:35-44.
22. Stevens RG. 2006. Artificial lighting in the industrialized world: Circadian disruption and breast cancer. Cancer Causes Control 17:501-507.
23. Stevens RG, Davis S. 1996. The melatonin hypothesis: Electric power and breast cancer. Environ Health Perspect 104 (Suppl 1) : 135-140.
24. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. 1981. Melatonin inhibition and pinealectomy enhancement of 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in the rat. Cancer Res 41:4432-4436.
25. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ. 1999. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:1672-1685.
26. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. 2002. MT (1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192:147-156.